<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment protocols for breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment protocols for breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment protocols for breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tim Brenner, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shrina Duggal, PharmD, BCOP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jim Natale, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Harold J Burstein, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 07, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12702398"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with breast cancer. Additional regimens may be added over time, particularly as treatment for breast cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy and immunotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with breast cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/788.html" rel="external">"Selection and administration of adjuvant chemotherapy for HER2-negative breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14225.html" rel="external">"General principles of neoadjuvant management of breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/83848.html" rel="external">"Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p></p><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy and immunotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy and immunotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class="headingAnchor" id="H12702620"><span class="h1">REGIMENS</span></p><p class="headingAnchor" id="H12702628"><span class="h2">Regimens for HER2-negative breast cancer (including HER2-low cancers)</span></p><p class="headingAnchor" id="H931995884"><span class="h3">TC (docetaxel plus cyclophosphamide)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef56545" href="/d/graphic/56545.html" rel="external">table 1</a>)</p><p class="headingAnchor" id="H931995909"><span class="h3">AC-T, dose dense (doxorubicin plus cyclophosphamide followed by paclitaxel)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef55933" href="/d/graphic/55933.html" rel="external">table 2</a>)</p><p class="headingAnchor" id="H931995934"><span class="h3">AC (doxorubicin plus cyclophosphamide)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef78493" href="/d/graphic/78493.html" rel="external">table 3</a>)</p><p class="headingAnchor" id="H527737597"><span class="h3">TAC (docetaxel, doxorubicin, and cyclophosphamide)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef89386" href="/d/graphic/89386.html" rel="external">table 4</a>)</p><p class="headingAnchor" id="H931996017"><span class="h3">Oral CMF (oral cyclophosphamide plus methotrexate and fluorouracil)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef69601" href="/d/graphic/69601.html" rel="external">table 5</a>)</p><p class="headingAnchor" id="H29982684"><span class="h3">IV CMF (IV cyclophosphamide plus methotrexate and fluorouracil)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86827" href="/d/graphic/86827.html" rel="external">table 6</a>)</p><p class="headingAnchor" id="H29982798"><span class="h3">FEC (fluorouracil, epirubicin, plus cyclophosphamide)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86828" href="/d/graphic/86828.html" rel="external">table 7</a>)</p><p class="headingAnchor" id="H29982691"><span class="h3">FEC followed by weekly paclitaxel</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86825" href="/d/graphic/86825.html" rel="external">table 8</a>)</p><p class="headingAnchor" id="H1232629016"><span class="h3">FEC followed by weekly docetaxel</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef86826" href="/d/graphic/86826.html" rel="external">table 9</a>)</p><p class="headingAnchor" id="H1874344937"><span class="h3">Trastuzumab deruxtecan</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef140174" href="/d/graphic/140174.html" rel="external">table 10</a>)</p><p class="headingAnchor" id="H12702676"><span class="h2">Regimens for HER2-positive breast cancer</span></p><p class="headingAnchor" id="H1659421429"><span class="h3">TH (paclitaxel and trastuzumab)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef119872" href="/d/graphic/119872.html" rel="external">table 11</a>)</p><p class="headingAnchor" id="H3347880580"><span class="h3">TCH (docetaxel, carboplatin, and trastuzumab)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef119331" href="/d/graphic/119331.html" rel="external">table 12</a>)</p><p class="headingAnchor" id="H3858911648"><span class="h3">TCHP (trastuzumab, pertuzumab, carboplatin, and docetaxel)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef96372" href="/d/graphic/96372.html" rel="external">table 13</a>)</p><p class="headingAnchor" id="H2574148646"><span class="h3">AC-TH (doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef54687" href="/d/graphic/54687.html" rel="external">table 14</a>)</p><p class="headingAnchor" id="H3694776182"><span class="h3">AC-THP (doxorubicin and cyclophosphamide followed by paclitaxel, trastuzumab, and pertuzumab)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef120643" href="/d/graphic/120643.html" rel="external">table 15</a>)</p><p class="headingAnchor" id="H2180377747"><span class="h3">FEC-THP (FEC followed by docetaxel, pertuzumab, and trastuzumab)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef96464" href="/d/graphic/96464.html" rel="external">table 16</a>)</p><p class="headingAnchor" id="H1974327486"><span class="h3">THP-FEC-H (neoadjuvant docetaxel, trastuzumab, and pertuzumab followed by adjuvant FEC, followed by trastuzumab</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef96371" href="/d/graphic/96371.html" rel="external">table 17</a>)</p><p class="headingAnchor" id="H3136894429"><span class="h3">THP (docetaxel, trastuzumab, and pertuzumab)</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef96342" href="/d/graphic/96342.html" rel="external">table 18</a>)</p><p class="headingAnchor" id="H96994675"><span class="h3">Ado-trastuzumab emtansine</span><span class="headingEndMark"> — </span> (<a class="graphic graphic_table graphicRef140175" href="/d/graphic/140175.html" rel="external">table 19</a>)</p><p class="headingAnchor" id="H4033123365"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H793247427"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Scott M Wirth, PharmD, BCOP, who contributed to an earlier version of this topic review.</p></div><div id="topicVersionRevision">Topic 85677 Version 29.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
